Clinical Trials Browser

Phase 1/2 × Lymphoma, Follicular × ublituximab × Clear all

NCT05152459 2023-05-31

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Phase 1/2 Withdrawn

Lymphoma, Follicular